Browsing Tag
Columvi
4 posts
Roche’s Columvi shows durable three-year overall survival edge over Rituxan in phase III STARGLO trial
Find out how Roche’s Columvi delivered a durable three-year survival advantage in the phase III STARGLO lymphoma trial and what it means for patients and investors.
Genentech’s Columvi combo fails to secure FDA approval for second-line DLBCL use
FDA rejects Genentech’s sBLA for Columvi-GemOx in second-line DLBCL treatment; survival benefit data deemed insufficient for U.S. approval.
Genentech faces FDA setback for Columvi GemOx in second-line diffuse large B-cell lymphoma as SKYGLO trial becomes key to future U.S. expansion
Genentech’s Columvi GemOx sBLA faces FDA rejection in second-line DLBCL. Analysts await SKYGLO trial data for U.S. approval prospects. Learn more.
Roche’s Columvi extends survival in Phase III DLBCL study
Roche has revealed promising outcomes from its Phase III STARGLO study, showcasing significant advancements in treating relapsed or…